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Abstract
Background: It is challenging to obtain a similar access to positron emission tomography/computed tomography
(PET-CT) within the whole region served. In the subarctic and arctic region of Norway, significant distances, weather
conditions and seasonable darkness have been challenging when the health care provider has aimed for a high
quality PET-CT service with similar availability to all inhabitants.
Methods: The PET-CT service at the University Hospital of North Norway (UNN) was established in May 2010. The
glucose analogue tracer fluorine-18 fluorodeoxyglucose (FDG) was delivered from Helsinki, Finland. An ambulatory
PET-CT scanner was initially employed and a permanent local one was introduced in October 2011. In March 2014,
we analysed retrospectively all data on the PET-CT exams performed at the Section of Nuclear Medicine,
Department of Radiology during a 32 months time period 2010–13. The following patient data were recorded:
gender, age, diagnosis, residence and distance of travelling. There were in total 796 exams in 706 patients.
Results: Four hundred sixty-one PET-CT exams per million inhabitants were, on average, performed per year. Lung
cancer (32.7 %), malignant melanoma (11.3 %), colorectal cancer (10.9 %) and lymphoma (9.7 %) constituted
two-thirds of all exams. Three-fourths were males and the median age was 63.5 years (range 15.2–91.4 years). The
access to PET-CT exam varied within the region. The southern county (Nordland) experienced a significantly less
access (p < 0.0001) to the regional service. Except for malignant melanoma, this finding was observed in all major
cancer subgroups. In colorectal cancer and lymphoma a lower consumption of PET-CT was also observed in the
northeastern county (Finnmark). Patients’ mean distance of travelling by car (one way) was 373 km (median 313 km,
range 5–936 km).
Conclusion: PET-CT was not similarly available within the region. Especially, inhabitants in the southern county
experienced less access to the regional service. National and regional standards of care, new scanners and
improved collaboration between hospital trusts may alter this situation.
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Background
The integral role of PET using FDG in the staging of
several malignancies and in the evaluation of inflamma-
tory disease has been established [1]. There has been an
increasing interest in the prognostic and predictive role
of FDG-PET scans. Studies have shown that absence of
metabolic response to neoadjuvant therapy correlates
with poor pathologic response.
The need for PET/CT scanner installations in Norway
was first launched in 2000 [2]. Health care decision makers
have since then ordered in total six Health Technology
Assessments (HTAs). The early funding was made pos-
sible in 2004 through collaboration between the Ministry
of Education and Research, Norwegian Research Council
and Amersham Health AS [3]. Somewhat surprising, the
Ministry of Health and Care Services was not present
among the financiers. The first PET-CT was located in
Oslo (southeastern region) and the financiers stated that
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the new diagnostic tool should be of benefit to all Norwe-
gian health regions. In 2009, the Norwegian Knowledge
Centre calculated the necessary number of PET-CT scan-
ners to serve the Norwegian population [4]. They con-
cluded the figure to be between 4 and 14 PET-scanners,
depending on whether this technology was implemented
in radiation planning or not [4]. At this time indications
for PET-CT were lung cancer and Hodgkin’s lymphoma.
Following the introduction of the PET-CT modality in
Norway, it became clear from the early evaluations that the
availability to this service was dropping with the distance to
the PET-centres. This was especially observed in northern
Norway. To counteract this tendency and improve the ser-
vice to the population of Northern Norway, the University
Hospital of North Norway (UNN) initiated a process to im-
plement a PET-CT scanner in Tromsø. Northern Norway
covers almost half of Norway’s land mass and is about two-
thirds of the size of the UK, but the population is only
470,000 inhabitants. They live in three counties named
Finnmark, Troms and Nordland and 2500 people live in
the Norwegian arctic, mainly on the Svalbard islands. Sig-
nificant distances to national health care facilities in south-
ern and western Norway and health care facilities within
northern Norway have been a constant challenge to the
Northern Norway Regional Health Authority (NNRHA)
trust. The northern area has a subarctic and arctic climate.
Cold and rough weather conditions, long distances, season-
able darkness and snow have to be handled. Consequently,
it is of importance to clarify whether a PET-centre in this
remote geographical area, outside major cities and Ivy
League academic institutions, can offer equal availability of
PET services regardless of geography and socio-economics.
Methods
The service analysed
The evolution of nuclear medicine during the early days of
this millennium pointed clearly to the need for a PET–CT
scanner in the northern region. However, the University
Hospital of North Norway’s location at the top of Europe
and its limited economic resources called for a cost-
effective service. The city of Tromsø is situated at the
centre of northern Norway with more than 800 kilometres
(km) by car to the southern border of Nordland County
and 900 km to the Russian border in the east of Finnmark
County. Details are shown on the map in Fig. 1. The dis-
tances from Tromsø to the nearest national cyclotrons
Fig. 1 The Scandinavian peninsula with Norway. The route from Helsinki to Tromsø is shown. White stars marks cities in Norway with PET-CT scanners
(Bergen, Oslo, Tromsø). The white lines illustrate the borders between counties in Norway and Sweden. The map was provided and given permission
to reproduce by The Norwegian Mapping Authority/Northern Norway Regional Health Authority
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(Bergen 1809 km and Oslo 1641 km) are significant.
Consequently, the best logistics were obtained through co-
operation with the Finnish company MAP Medical
Technologies OY in Helsinki. The distance is 1355 km.
FDG was produced in Helsinki in the early morning
05.40 a.m. Finnish time (04.40 a.m. Norwegian time) and
transported by Finnair® to the city of Rovaniemi in northern
Finland. The tracer was then transported further by air-
plane to Tromsø by Oulun Tilauslento OY. The batch
reached Tromsø 5 h later at 09.40 a.m. local time and could
be used until 3 p.m. To make this transportation possible
(2.75 half-lives of F-18 FDG), the activity when ready for
transportation was 45 GBq. The activity when arriving our
lab in Tromsø was 6.7 GBq. The first patient was examined
in May 2010 and the capacity was 8 patients every Wednes-
day. Initially, Alliance Medical served several hospitals in
Scandinavia employing a PET-CT placed in a semitrailer.
This trailer was driven according to a specific route visiting
hospital in Tartu and Tallin in Estland, Kuopio and Oulu in
Finland, Tromsø in Norway and Umeå, Falun and Örebro
in Sweden. The semitrailer solution was replaced in Octo-
ber 2011 by a stationary PET-CT scanner. In November
2012 a permanent PET-CT service was established. This
was made possible by a private donation by businessman
Trond Mohn.
Data included
Data included all consecutive PET-CT exams performed at
the Section of Nuclear Medicine Department of Radiology
UNN. There were in total 796 exams in 706 patients. In
April 2014 all data were retrospectively analysed. The 4 years
time period 2010–13 was selected and the following data
were recorded: gender, age, diagnosis, number of exams,
place of living and distance of travelling. Inhabitants of
Svalbard (three patients) were included in the Finnmark fig-
ures. However, patients living on the Svalbard islands were
not included when the distance to Tromsø was calculated.
Distance was calculated in kilometres (km) from the com-
munity of each patient to the UNN in Tromsø employing
the NAF converter (www.naf.no). The converter measured
the distance by road. In case of alternatives, the shortest dis-
tance was chosen.
The mean number of inhabitants 2010–2013 in the three
counties (Finnmark, Troms and Nordland) of northern
Norway was calculated according to Statistics Norway
(www.ssb.no). The mean figures were 73,649, 158,279 and
237,871 inhabitants, respectively.
Quality control, statistical analysis and authorisation
Individual data were recorded from the database at the
Section of Nuclear Medicine, Department of Radiology,
UNN. Microsoft Excel Mac 2011 was used for the final
database and the IBM SPSS Statistics 2011 was used for
calculations and statistical analysis. Descriptive statistics and
Chi-squared test for 2×2 tables were used for the compari-
son between subgroups. Significance was set to 5 %. The
study was carried out as a quality of care analysis and conse-
quently no ethical committee or Data Inspectorate approval
was necessary. Similarly, no approval from the Regional
Committees for Medical and Health Research Ethics (REK)
or from the Norwegian Social Science Data Services (NSD)
was necessary.
Results
During the early years (2010–2011) a total of 7.5 out of 30
planned days of PET-CT scanning were cancelled (25 %)
between 9th of August and 15th of April. The reason was
technical scanner failure. The ambulatory PET-CT scanner
transportation on rough Nordic winter roads was clearly a
risky business. Following the establishment of the perman-
ent local PET-CT scanner, these early problems were
solved.
During study period a total of 796 exams were performed
in 706 patients (1.13 exams/patient). The highest re-
examination rate (1.5) was observed among malignant
melanoma patients. The figures constituted annually 461
PET-CT exams per million inhabitants and lung cancer
(32.7 %), malignant melanoma (11.3 %), colorectal cancer
(10.9 %) and lymphoma (9.7 %) constituted two thirds of all
exams. Details are shown in Table 1.
There was no significant difference in age between
genders. The mean age among females and men were
59.8 years (median 62.6 years, range 20.8–85.8 years)
and 61.8 years (median 64.9 years, range 15.2–
91.4 years), respectively.
Whereas the counties of Finnmark and Troms generally
had a similar access to PET-CT, the population of Nordland
County experienced a different situation. During study
period, the ratio (percentage of PET-CT scans/population)
was 0.7 and 1.3 (Table 2) (p < 0.0001), and the number of
patients with PET/CT exams during the 4 year period dif-
fered significantly between the three counties (p < 0.0001).
The proportion of the population undergoing a PET-CT
scan in each northern county during study period were
Nordland 0.10 %, Troms 0.20 % and Finnmark 0.19 %,
respectively. Looking at the four major cancer groups, a
similar availability in all counties was only observed in
malignant melanoma. The greatest difference was seen in
the lymphoma group. Details are shown in Table 2. Due
to low numbers of cancer patients with unknown origin,
we did not run any comparison between counties in this
setting.
The mean distance (one-way) from patients’ place of living
to Tromsø (by car) was 373 km (median 313 km, range 5–
936 km). The corresponding figures in each county were:
Finnmark 610 km (median 568 km, range 397–863 km),
Troms 130 km (median 123 km, range 5–332 km) and
Nordland 545 km (median 550 km, range 244–936 km).
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Discussion
In this study, we have documented that the number of
PET exams in northern Norway increased from 268 in
2010 to 564 exams/million population in 2013. These
figures are low compared to Norway in general and
neighbouring countries. The finding must be seen in the
context of relatively few PET-CT scanners in Norway
and especially in our region. The number of PET-CT
scanners per million inhabitants in Europe varied in
2009 between 0.3 (Ireland) and 3.9 (Denmark) and the
Norwegian figure was 0.8 [4]. In the Nordic countries, the
first PET facilities were established in Sweden in the late
1970s followed by Finland in 1988 and Denmark in 1989
[5]. Since the introduction of PET at the Norwegian
Radium Hospital in Oslo back in 2005, the total number of
PET-exams in Norway has increased from 80 in 2005 to
7525 in 2014. Employing the national population data of
2013 (www.ssb.no) (population 5.1 million), the corre-
sponding national annual number of exams per million was
calculated as 1475. Following the implementation of a PET
scanner in Bergen (western Norway) in 2009, the figures of
the western region rose from 293 exams in 2009 to 1616
exams in 2014 (personal communication dr. Michael
Biermann, Haukeland University Hospital, Bergen Norway).
With a population of 1074 million (www.helse-vest.no), the
2014 figure of the western region can be calculated as 1504.
Table 1 An overview of PET-CT scans performed and number of patients examined (2010–2013)
Exams Patients
Variable PET-CT % PET-CT % Exams/pt
Total 796 100 706 100.0
Sex Females 324 40.7 291 41.2 1.1
Males 472 59.3 415 58.8 1.1




County Finnmark 156 19.6 140 19.8 1.1
Troms 349 43.8 311 44.1 1.1
Nordland 282 35.4 249 35.3 1.1
Others/unknown 9 1.1 6 0.8 1.5
Diseases Lung cancer 260 32.7 246 34.8 1.1
Malignant melanoma 90 11.3 61 8.6 1.5
Colorectal cancer 87 10.9 76 10.8 1.1
Lymphoma 77 9.7 71 10.1 1.1
Head & neck carcinoma 44 5.5 40 5.7 1.1
Urogenital cancer 28 3.5 21 3.0 1.3
Thyreoid carcinoma 25 3.1 23 3.3 1.1
Gynaecological cancer 25 3.1 21 3.0 1.2
Upper GI-cancer 17 2.1 17 2.1 1.0
Breast cancer 8 1.0 8 1.1 1.0
Other cancers 14 1.6 13 1.8 1.1
Cancer, unknown origin 54 6.8 46 6.5 1.2
Inflammatory disease 51 6.4 44 6.2 1.2
Sarcoidosis 12 1.5 11 1.8 1.1
Others 4 0.5 2 0.3 2.0
Table 2 The ratio of PET-CT exams/population in total and in
each county of northern Norway is shown. The figure of all
three northern counties was set as 1.00. (For example: All exams
787 exams/470,000 inhabitants = 0.17 % = 1.00)
Nordland Troms Finnmark
Lung cancer 0.57 1.34 1.66
Malignant melanoma 0.99 1.02 0.99
Colorectal cancer 0.88 1.25 0.84
Lymphoma 0.67 1.62 0.74
All exams 0.71 1.32 1.26
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Similar findings may be indicated employing the data of
Høilund-Carlsen and colleagues [5] who reported a total of
6056 PET/CT examinations performed between 2006 and
2009 (3.8 years) in the Region of Southern Denmark
(1.2 million inhabitants). According to data from Stevens
presented at the annual meeting of the European Associ-
ation of Nuclear Medicine (EANM) in 2011, PET examina-
tions per million population in 2010 ranged within the
Western-European countries from around 1000 in U.K.
and Eire to 4000 in Italy (www.auntminnieeurope.com).
Looking to Canada, the Canadian Institute of Health In-
formation (www.cihi.ca) reported 62,668 PET-CT exams
performed in Canada in 2011–2012 giving a number of
exams/million of 1800 (34.8 million inhabitants). Around
20 % of the worldwide PET/CT installed base is located in
Europe [6]. Bedford and Maisey [7] calculated an increas-
ing need for PET scanners. In their mathematical model,
(employing U.K. data) the need was 2026 PET exams/mil-
lion population to cover all indications in cancer care.
Based on all these data, an underuse of PET-CT in our
region can be strongly indicated.
Furthermore, the regional service in northern Norway
was not equally accessible to all inhabitants within the
region. Inhabitants of Nordland County experienced a
significantly lower access rate. During the time period
2010–2012, a possible learning curve was indicated for the
clinicians in referring or not referring to PET. However,
data for 2013 were again deviating. A follow up study
including 2014–15 should be done to clarify whether any
learning curve can be concluded.
The distance from patients’ place of living to the PET
centre in Tromsø was significant. This is due to the fact
that the limited population (0.47 million) is scattered
within a significant geographic area (174,000 km2).
The most common diagnoses among patients under-
going PET-CT scan in our region were lung cancer,
malignant melanoma, colorectal cancer and lymphoma.
PET-CT has been documented the best non-invasive
technique for evaluation of lymph nodes and extrathora-
cal disease in lung cancer [8, 9]. Despite the fact that
PET in the management of non-small cell lung cancer
(NSCLC) has been clearly documented and included in
the national guideline [10], significant variations in the
pattern of use within northern Norway was disclosed.
The Norwegian guideline state that PET-CT is recom-
mended in all NSCLC patients considered candidates for
curative treatment. When small peripheral lesions (stage
1) are revealed, patients may be referred to the multidis-
ciplinary team (MDT) and undergo surgery without any
preoperative examination. The place of preoperative
PET-CT in small cell lung cancer (SCLC) has been less
documented [11], but suggested in the national guide-
lines. Langer and colleagues [12] did not observe any
place for PET-CT in response evaluation in lung cancer.
Differences between counties in our region could be
due to referrals from Nordland to the southeastern or
western PET centers in Norway. There could also be a
“leakage” of patients from the UNN due to waiting list/
time and episodes when the local scanner was out of ser-
vice. We therefore contacted the hospital trusts and got
information from their Department of Economics about
all PET-CT scans paid for during study period. This
revealed that the UNN had paid for 89 PET-CT exams
(2010–13) outside northern Norway. Similarly, Nordland
hospital had paid for 41 exams (2010–12). Correcting
for these figures, the significant less use of PET-CT
among patients in Nordland was still present.
Another fact may be differences in waiting time. Whereas
the MDTat the UNN had weekly appointments reserved at
the PET-CT scanner, this was not the fact for the MDT at
Nordland hospital. In the national guideline it is recom-
mended that PET-CT exams should not delay curative sur-
gery by more than 2 weeks. Employing our data, we could
not detect whether patients in Nordland underwent more
frequently curative surgery without any preoperative PET-
CT due to long waiting lists. However, due to our findings,
we have now reserved weekly appointments in Tromsø for
the Nordland hospital’s MDT.
The benefit of PET-CT in the follow up of malignant
melanoma has been debated. Recently, Danielsen and co-
workers [13] performed a systematic literature search and
identified 7 original studies on the diagnostic value of
FDG-PET in the follow-up of cutaneous malignant melan-
oma (CMM). The mean sensitivity of PET was 96 % and
the specificity was 92 %. The positive and negative predict-
ive values were, respectively, 92 and 95 %. They concluded
PET had a high diagnostic value and this indicated utility
in the routine follow-up program. However, the number
of prospective studies of high quality was scarce. The
Norwegian guideline for the diagnosis and follow up of
malignant melanoma presupposes that the patients are
well evaluated (including ultrasound, CT, MR or PET-CT)
prior to surgery. Especially prior to operation on regional
lymph node metastases or prior to resection of distant
metastasis, PET-CT has been considered useful [14–16].
The three northern counties (Nordland, Troms and Finn-
mark) had similar age adjusted incidence rates of malig-
nant melanoma (2007–2011) per 100.000 person-years
[17]. Details are shown in Table 3. Looking at these
figures, it was satisfactory to observe the equal access to
PET-CT among this group of cancer patients. The strong
cooperation within plastic surgery between the two major
hospitals located in Bodø and Tromsø and the ambulatory
service from Tromsø to Bodø (by plastic surgeons) may
explain this similar standard of care. We searched for data
on PET and malignant melanoma from other Norwegian
regions, but revealed only one unreported study from
2007 (Oslo University Hospital) concluding the disease
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accounted for 3 % of all PET exams. Due to different inci-
dence rates and later updates of the national guideline
[16], this data is not comparable to our findings.
According to the national guideline [18], PET-CT has so
far no place in primary evaluation of patients diagnosed
with colorectal carcinoma (CRC). At present, PET-CT has
been reserved for the examination of patients with sus-
pected local recurrence when other diagnostic tools have
been inconclusive. It is also recommended in the pre-
operative setting when curative resection of liver metasta-
ses has been planned. This is in coherence with our
finding that CRC constituted only 10.8 % of the patients
examined despite this disease is the most common cancer
in Norway. However, different use of PET exams between
counties should be further explored. It could be specu-
lated that differences may be due to later presentation to
the health care system due to less general accessibility and
less availability to early diagnostics like endoscopy. How-
ever, the 5 years relative survival of colon cancer does not
support such a statement (Table 3). The northern region
has similar results as other health regions, according to
national quality data (www.helsenorge.no) [17]. In the fu-
ture, there are reasons to believe PET-CT may be more
commonly used in CRC due to advocates for the imple-
mentation of this diagnostic tool in the follow up pro-
gram. Recently, a cohort of 132 patients, treated by
surgery with curative intent, was included in a follow-up
analysis [19]. Patients were followed prospectively with
scheduled controls at 3, 6, 12 and 24 months after curative
surgery. The controls included CEA, chest X-ray, ultra-
sound, CT and PET supplemented by clinical examination.
The end-point was recurrence. Sensitivity and specificity
was estimated 2 years after surgery. Twenty-five patients
experienced recurrence, detected at scheduled controls
(n = 18) and at intervals between them (n = 7). The results
of CT and PET were correlated with recurrence. CT com-
bined with PET had the highest specificity and sensitivity.
A total of 72 % of recurrences were detected at scheduled
controls. The findings supported a strict follow-up pro-
gram following curative surgery for colorectal cancer. The
authors suggested that FDG-PET combined with CT
should be included in control programs.
The fourth major patient group in our study was lymph-
oma [20]. According to the national guideline, PET-CT was
requested in research settings, for example in response
evaluation [20]. The focus on PET-CT in the research set-
ting may reflect the significant “overuse” of PET-CT in the
county (Troms) being the host of the University hospital.
Several researchers have published the potential prognostic
impact of PET-CT in lymphoma [21–23]. Gallicchio and
colleagues [21] evaluated the prognostic significance of
standardized uptake value (SUVmax), metabolic tumor
volume (MTV), and total lesion glycolysis (TLG) obtained
by FDG PET-CT in patients with diffuse large B-cell
lymphomas (DLBCL). The SUV may be calculated either
pixel-wise yielding a parametric image, or over a region of
interest. This may be done for any image acquired at time
point t, or for all images of a dynamic series acquired at
multiple time points. MTV may be derived from SUV im-
ages and may be of interest for both target volume defin-
ition in radiotherapy and monitoring response to therapy.
TLG may be defined as (SUVavg) × (tumor volume), with a
threshold of 45 % SUVmax in the volume of interest.
Kaplan-Meier survival analysis for SUVmax showed a sig-
nificantly better event free survival in patients presenting
higher values as compared to those with lower values. In
Hodgkin lymphoma patients, routine PET-CT in first re-
mission has not been shown superior to clinical follow-up
for patients with no residual mass [24].
PET-CT was also used in carcinoma of unknown pri-
mary (CUP) in our study. We did not compare the three
northern counties with regard to CUP due to low num-
bers (54 patients). Breuer and colleagues [25] have pub-
lished the benefit of PET-CT in this setting. They
concluded FDG PET-CT a helpful tool for the
Table 3 The table shows the age adjusted incidence and
mortality rates per 100,000 and 5-years relative survival of all
cancer, lung cancer, malignant melanoma, colon cancer and
non-Hodgkin lymphoma (NHL) in Norway and each county in
northern Norway. The figures are based on data from the
Norwegian Cancer Registry for 2009–2013 [17]
Cancer Region Incidence Mortality 5-years surv.
F M F M F M
All Norway 302.0 374.1 85.9 115.5 68.9 68.5
Nordland 284.1 351.9 84.0 116.0 67.2 68.5
Troms 276.9 353.6 83.6 106.2 66.7 70.7
Finnmark 258.9 333.4 80.2 129.7 66.9 58.2
Lung Norway 26.0 34.9 17.6 26.2 18.8 13.1
Nordland 23.4 33.5 18.5 25.3 17.0 11.8
Troms 24.2 33.9 18.2 24.2 17.0 17.1
Finnmark 26.4 51.2 19.4 38.3 20.6 11.9
Mal.mel. Norway 21.1 20.2 2.6 4.3 88.3 79.0
Nordland 11.6 12.5 2.1 3.0 75.7 77.8
Troms 14.3 12.5 2.0 2.9 91.9 87.3
Finnmark 11.2 8.9 1.7 1.9 88.7 74.0
Colon Norway 24.6 27.1 9.0 11.0 63.3 59.5
Nordland 24.8 27.7 8.2 10.6 64.9 63.5
Troms 22.8 25.4 8.5 9.9 64.9 66.3
Finnmark 21.7 19.3 5.4 8.6 77.3 48.5
NHL Norway 9.6 13.2 1.9 3.4 76.4 70.5
Nordland 11.0 12.7 2.7 3.3 82.4 75.8
Troms 9.5 11.5 1.9 2.5 88.5 77.2
Finnmark 9.3 13.5 1.5 2.6 76.2 66.8
F female, M male
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identification of the primary tumor in patients with CUP.
In 26 % of the patients, a primary tumor was identified.
The tool was also able to provide an accurate assessment
of prognosis based on the extent of the disease without
the need for identification of the primary tumor. Kaplan-
Meier analysis revealed 3-year survival rates of 73 % (with-
out evidence of malignancy), 71 % (locoregional disease),
and 23 % (extensive disease), respectively.
Our study was not intended as a clinical paper on diag-
nostic performance. We focused on basic demographics of
northern Norway. We did not include/assess clinical data
on incidence numbers and disease stages at diagnosis in
the three regions compared to the rest of Norway. How-
ever, incidence data are available from the Cancer Registry
of Norway [17]. As illustrated in Table 3, there are some
differences. Lung cancer is more common in Finnmark
and malignant melanoma is less common in northern
Norway. However, these differences cannot explain the
variations in accessibility to PET-CT within our region.
Hybrid PET-MRI scanners are now available for clinical
use. PET-MRI combines the unique features of MR im-
aging including excellent soft tissue contrast, diffusion-
weighted imaging, dynamic contrast-enhanced imaging
and other specialized sequences as well as MRI spectros-
copy with the quantitative physiologic information that is
provided by PET. There are potential competitive advan-
tages (for example the radiation dose) of PET-MRI over
PET-CT. In the future, we therefore plan for a PET-CT
and a PET-MRI service and a cyclotron located in Tromsø
and running from 2017. Furthermore, a PET-CT scanner
has been planned at Nordland hospital in Bodø. Hopefully
these plans together with a follow up of this study may
improve the equal availability of PET services in our
region.
Conclusion
PET-CT was not similarly accessible within the region.
Especially, inhabitants in the southern region experi-
enced less access to the service. National and regional
standards of care and improved collaboration between
hospital trusts may alter this situation. It was possible,
but challenging to run a PET-CT service in the northern
sub-arctic region of Norway. An ambulatory scanner is
not recommended. In the future a local cyclotron is
preferable.
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